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Abstract: We aimed to evaluate the evidence on screening and treatment for two parasitic
infections—schistosomiasis and strongyloidiasis—among migrants from endemic countries arriving
in the European Union and European Economic Area (EU/EEA). We conducted a systematic
search of multiple databases to identify systematic reviews and meta-analyses published between
1 January 1993 and 30 May 2016 presenting evidence on diagnostic and treatment efficacy and
cost-effectiveness. We conducted additional systematic search for individual studies published
between 2010 and 2017. We assessed the methodological quality of reviews and studies using the
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AMSTAR, Newcastle–Ottawa Scale and QUADAS-II tools. Study synthesis and assessment of the
certainty of the evidence was performed using GRADE (Grading of Recommendations Assessment,
Development and Evaluation) approach. We included 28 systematic reviews and individual studies
in this review. The GRADE certainty of evidence was low for the effectiveness of screening techniques
and moderate to high for treatment efficacy. Antibody-detecting serological tests are the most
effective screening tests for detection of both schistosomiasis and strongyloidiasis in low-endemicity
settings, because they have higher sensitivity than conventional parasitological methods. Short
courses of praziquantel and ivermectin were safe and highly effective and cost-effective in treating
schistosomiasis and strongyloidiasis, respectively. Economic modelling suggests presumptive
single-dose treatment of strongyloidiasis with ivermectin for all migrants is likely cost-effective,
but feasibility of this strategy has yet to be demonstrated in clinical studies. The evidence supports
screening and treatment for schistosomiasis and strongyloidiasis in migrants from endemic countries,
to reduce morbidity and mortality.
Keywords: migrant populations; schistosomiasis/schistosoma; strongyloidiasis/strongyloides;
screening/diagnosis; treatment; public health; GRADE
1. Introduction
The public health importance of schistosomiasis and strongyloidiasis has increased in
non-endemic regions as a result of growing global migration [1,2]. Schistosomiasis is caused by
species of the trematode Schistosoma spp. Sc. mansoni is the most prevalent in Africa, the Americas,
the Middle East and the West Indies, followed by Sc. haematobium in Africa and the Middle East and Sc.
japonicum in east and south-east Asia [3]. Sub-Saharan African countries account for 90% of reported
cases globally [3]. Prevalence rates of 10–50% for Sc. haematobium infections have been reported in
some countries in sub-Saharan Africa and the Middle East [4], and prevalence rates of 1–40% have been
reported for Sc. mansoni in sub-Saharan Africa and South America and for Sc. japonicum in Indonesia,
parts of China and south-east Asia [5].
Strongyloidiasis is caused by the nematode Strongyloides stercoralis and, although it generally
occurs in sub-tropical and tropical countries, it can be present in temperate countries where conditions
are favourable [6]. The global burden of both diseases has been underestimated because of the poor
sensitivity of diagnostic methods used in low-resource settings [6], but recent estimates indicate
that around 370 million people are infected with St. stercoralis [7] and more than 200 million are
infected with schistosomiasis causing a loss of more than 1.53 million disability-adjusted life years
(DALYs) [4,5,8,9].
Few studies have assessed the prevalence schistosomiasis in European countries, but recent data
show rates above 17% in migrants from sub-Saharan Africa [10]; prevalence of strongyloidiasis among
refugee populations originating from south-east Asia and Africa was reported to be between 0.8%
and 4.3% using microscopy; higher rates of between 9% and 77% using antibody detection assays
were reported among refugees from south-east Asia [11]. Prevalence rates of 3.3%, 4.2% and 5.6%
were reported in Italy, Spain and France, respectively, mainly in migrant populations or expatriates,
without specifying diagnostic methods [6].
From all parasitic infections that may be highly prevalent among migrants, schistosomiasis and
strongyloidiasis have several characteristics which support the rationale for screening based on the
classical principles of Wilson and Jungner [12]. First, both infections are of particular importance,
besides being as highly prevalent as other parasitic infections, they can cause long-term complications
and severe consequences. Schistosomiasis is associated with chronic urogenital, hepato-intestinal
and central nervous system complications [9,13–15]. St. stercoralis can cause disseminated infections
or hyper infections with fatal outcomes in immunosuppressed patients (e.g., transplant recipients,
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those on corticosteroid therapy, with malignancies or co-infections with human T-cell lymphotropic
virus-1 (HTLV-1)) [16]. In addition, there is a potential risk of transmission in the EU/EEA, either
through organ transplantation in the case of strongyloidiasis [17] or through a favourable environment
for the intermediate host, as in recent autochthonous cases of urinary schistosomiasis in Corsica,
France which is not the case from many other parasitic infections [11,18]. Second, most infections
are asymptomatic [13,19,20] and those infected are either unaware of their infection [19] or have very
mild unspecific symptoms [3]. Third, both are chronic infections if untreated [19]. Schistosomiasis can
remain as a sub-clinical infection for many years [3], and St. stercoralis replicates indefinitely inside the
human host, causing lifelong infection if untreated [19].
Fourth, screening could be based on a simple and widely accessible technology, including
commercially available serological test with a reasonable cost. In this sense, diagnosis of both infections
based on microscopy has high specificity but low sensitivity [19,21,22]. Antibody-detecting serological
tests offer higher sensitivity, at the expense of specificity, and have been shown to be useful in countries
with low endemicity [19,22,23]. Finally, treatments for both infections are universally accepted with a
high efficacy rate and low rate of adverse events. Praziquantel and ivermectin are the drugs of choice
for treating schistosomiasis and strongyloidiasis, respectively [7,13].
In the last ten years, there has been a significant increase in migration patterns to the EU/EEA
with some fluctuations in the volume and type of migration from year to year [24,25]. In 2017, migrants,
here defined as being born abroad, made up 11% of this population, with 4% being born in another
EU/EEA country and 7% originating from outside the EU/EEA [26]. There is an increased number
of asylum applications with 56% of the 2,672,000 asylum decisions being positive between 2015 to
2017 [27]. Half of those denied asylum can be expected to leave, adding 580,000 to the EU/EEA’s total
number of irregular migrants [28].
There is a notable gap in data collection on the disease burden, public health management, and in
the surveillance for imported diseases in migrants arriving from endemic areas to EU/EEA. Geographic
differences in disease distribution between global regions, influenced by increasing migration and
population mobility from high endemic to non-endemic areas, remains an ongoing challenge to
surveillance programmes and hampers the implementation of health policies concerning migrant
health screening strategies [29,30].
There have been several systematic reviews addressing how effective are approaches to migrant
screening infectious diseases in Europe [31–33], however parasitic infections are not adequately
covered. Therefore, given the recent increase in migrants to the EU/EEA from endemic countries,
there is a need for public health guidelines on the optimal approach to screening for schistosomiasis and
strongyloidiasis [34–36]. In this systematic review, we assessed the effectiveness (and cost-effectiveness)
of screening and management of these two parasitic infections in migrant populations.
2. Methods
The review was one of six systematic reviews conducted under the auspices of a European Centre
for Disease Prevention and Control (ECDC) project to develop guidance on screening for hepatitis C,
hepatitis B, HIV, tuberculosis, vaccine-preventable diseases and parasitic infections in newly-arrived
migrants to the EU/EEA [37]. The review group followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines for the reporting of this systematic review [38].
The review protocol and methods assembled by a team of methodologists and clinicians with disease
expertise was registered in Prospero (CRD42016045798) and published [39].
Our key research question was:
What are the most effective screening and treatment options for schistosomiasis and
strongyloidiasis in migrant populations arriving from endemic regions in the EU/EEA?
To address this, we developed a logic model, prioritised outcomes important for the patient, and
developed key questions along the evidence pathway (Appendix A). These key questions included:
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(i) What are the best diagnostic tests to detect these infections non-endemic settings?
(ii) How effective are the drugs to treat them and what are the associated adverse events?
(iii) What are the most cost-effective screening and treatment options for schistosomiasis and
strongyloidiasis in migrant populations from endemic regions in the EU/EEA?
2.1. Search Strategy and Selection Criteria
We searched for systematic reviews and meta-analyses in MEDLINE, Embase-ELSEVIER,
the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Epistemonikos, the
Database of Abstracts of Reviews of Effects (DARE) and the Cochrane Database of Systematic Reviews
(CDSR) for evidence on effectiveness. Our search used a combination of the key terms: ‘Immigrant’,
‘Strongyloides’, ‘Schistosomiasis’, ‘endemicity’, ‘prevalence’, ‘screening’, ‘migrant screening’, ‘mass
screening’, ‘early detection’, ‘health impact assessment’ and ‘cost-effectiveness’ (Appendix B).
The primary inclusion populations were migrants and refugees. We considered as main outcomes:
cure, mortality, morbidity, adverse effects, health equity, quality of life and test accuracy measures
(sensitivity and specificity). Also, we searched the National Health System (NHS) Economic Evaluation
Database, the Health Economic Evaluations Database, the Cost Effectiveness Analysis Registry and
Google Scholar for evidence on cost-effectiveness. We also identified any reviews on prevalence of the
two infections. We restricted the search to studies published between 1 January 1993 and 30 May 2016.
We did not apply language restrictions, and where we identified more than one version of a systematic
review, we included the most recent. For the economic evidence, systematic reviews and primary
studies of resource use, costs or cost-effectiveness of screening for schistosomiasis or strongyloidiasis
with or without treatment were identified using specific search terms including (“costs and cost
analysis”; “cost effectiveness analysis”; “costs.tw”; “cost$.mp”; “cost effective$.tw”; “cost-benefit
analys$.mp” “health care costs.mp”) combined with clinical criteria. We reported all the costs in
the local currency of the study setting or country, and in Euros using the Cochrane methods group
purchasing power parity currency conversion calculator for the given year [40]. We also searched
grey literature for published guidelines and reports on screening and prevention programme from
the United States (U.S.) Centers for Disease Control and Prevention, ECDC, Joint United Nations
Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO).
2.2. Additional Included Studies
Due to the limited evidence obtained from the initial search, we conducted an updated systematic
search of six databases (MEDLINE, Embase-ELSEVIER, CINAHL, CDSR, DARE, Cochrane CENTRAL
and Latin American Literature in Health Sciences—LILACS). We included relevant primary studies on
diagnostic or screening tools for schistosomiasis (January 2010–February 2017) and strongyloidiasis
(January 2012–February 2017). References of included primary studies were searched to identify other
relevant studies.
2.3. Study Selection, Quality Assessment, and Synthesis
We included systematic reviews and evidence-based review guidelines which addressed each key
question. When no systematic review was identified, we used primary studies. Two team members
independently screened the titles and abstracts, followed by full-text assessments for eligibility
of studies on prevalence, screening and treatment effectiveness, and related key questions (Eric
Agbata, Nadia Montero) and of studies on cost-effectiveness (Nick Rowbotham, Rachael Morton).
Disagreements were resolved by consensus or the involvement of a third author (AR). We assessed
the methodological quality of reviews using AMSTAR [41] or Newcastle–Ottawa Scale [42] for
reviews and observational studies respectively. We assessed the methodological quality of included
primary studies on diagnostic effectiveness using the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS II) tool [43]. Synthesis of the studies and assessment of the certainty of the
evidence for systematic reviews and individual studies was performed using GRADE (Grading
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of Recommendations Assessment, Development and Evaluation) methods, including Summary of
Findings tables and Evidence to Decision tables [37]. For cost-effectiveness studies, we extracted
the following data: economic study design (e.g., cost–utility analysis, Markov model), description
of the case base population, the intervention and comparator, the absolute and relative difference in
resource use and cost-effectiveness (e.g., incremental net benefit (INB) or incremental cost-effectiveness
ratio (ICER).
3. Results
The first systematic search yielded, after removal of duplicates, 662 systematic reviews for
which we screened titles and abstracts. Of the 26 systematic reviews selected for full-text screening,
we included 11 systematic reviews which focused on the efficacy of diagnosis and treatment of
schistosomiasis (n = 8) and strongyloidiasis (n = 3) (Figure 1) [19,44–53]. The updated systematic
search for diagnostic testing accuracy studies for schistosomiasis yielded after de-duplication 1961
citations for the screening of titles and abstracts. Of the 30 articles selected for full-text screening,
we included seven primary studies (Figure 2) [54–60]. One more primary research was identified later
and included [61]. Another systematic search performed for diagnostic testing accuracy evidence for
strongyloidiasis yielded 497 records after de-duplication; titles and abstracts were screened, and of
the 24 papers selected for full-text screening, we included three primary studies (Figure 3) [62–64].
For the economic evidence, the search strategy yielded 160 studies after de-duplication. We retrieved
20 studies after title and abstract screening, of which six studies (four decision-analytic models for
economic evaluation and two costing studies) were finally included—four for strongyloidiasis and two
for schistosomiasis (Figure 4) [65–70]. Overall, we included 28 reviews and studies in this systematic
review (Tables 1–3).
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Table 1. Characteristics of included studies on diagnostic test effectiveness for schistosomiasis and strongyloidiasis, January 1993–February 2017.
Study Quality Design Population Intervention/Outcomes Results
Included systematic reviews of diagnostic tests to detect schistosomiasis
Danso
Appiah et al.,
2016 [53]
AMSTAR: 11/11
GRADE: low to
moderate-quality
evidence
Systematic review and
meta-analysis
Preschool children and infants,
school-aged children or adults
from high-/low-prevalence
locations
Intervention: POC CCA for
Sc. mansoni
Outcomes: detection of
egg-positive
urine—sensitivity/specificity (95%
CI:)
Sensitivity/specificity (95% CI)
POC CCA (single standard) 90% (84–94)/56% (39–71);
POC CCA (duplicate standard) 85% (80–88)/66%
(53–76); POC CCA (triplicate standard) 91%
(84–95)/56% (39–72)
Yang et al.,
2015 [50]
AMSTAR: 11/11
GRADE: low to
moderate-quality
evidence
Meta-analysis
Patients infected with
schistosomiasis in endemic areas;
mainly school children, Africa
and China
Intervention: questionnaire
screening for Schistosoma species.
Outcomes: sensitivity/specificity
(95% CI:)
Sensitivity/specificity (95%CI:)
Sc. haematobium 85% (84–86)/94% (94–94); Sc. mansoni
46% (45–47)/81% (80–82); Sc. japonicum 82%
(79–85)/59% (57–60)
Ochodo et
al., 2015 [44]
AMSTAR: 11/11
GRADE: very low to
low-quality evidence
Systematic review and
meta-analysis of RCTs
Individuals with active infection
with S. haematobium
Intervention: urine reagent strip
tests; circulating antigen tests in
urine/serum
Outcomes: sensitivity/specificity
(95% CI:)
Sensitivity/specificity (95% CI)
Sc. haematobuim: microhaematuria 75% (71–79)/87%
(84–90); proteinuria 61% (53–68)/82% (77–88);
leukocyturia 58% (44–71)/61% (34–88);
Sc. mansoni (CCA test) 89% (86–92)/55% (46–65)
King and
Bertsch, 2013
[45]
AMSTAR: 11/11
GRADE: low-quality
evidence
Systematic review and
meta-analysis of surveys
Schools, communities with
high/low prevalence, low
intensity groups in Africa
Intervention: dipstick test
Sc. haematobium.
Outcomes: sensitivity and
specificity (95% CI:), diagnostic
odds ratio (DOR)
Sensitivity/specificity (95% CI)
Detection of egg-positive urine 81% (79–83)/89%
(87–92).
In high-prevalence settings 80% (78–83)/86% (82–90);
lower in treated population 72% (61–78)/87% (81–94);
in lower intensity population subgroups 65%
(58–72)/82% (76–90)
Wang, et al.,
2012 [46]
AMSTAR: 7/11
GRADE: very low- to
low-quality evidence
Systematic review and
meta-analysis of RCTs,
retro-/pro-observational
studies
Infected patients with
schistosomiasis in control
programmes in China
Intervention: IHA and ELISA.
Outcomes: true positive rates,
sensitivity/specificity (95% CI:),
DOR
Sensitivity/specificity (95% CI)
IHA 75.6% (74–77)/73% (72–74) ELISA 84.9%
(83–87)/50.4% (49.2–51.6)
The DOR of IHA was 9.41 (95% CI: 5–18), and ELISA
4.78 (95% CI: 3.21–7.13)
Included primary studies of diagnostic tests to detect schistosomiasis
Espirito-Santo
et al., 2015
[57]
QUADAS-2-11/14
GRADE: very low- to
low-quality evidence
Cross-sectional
epidemiological survey in
areas of low prevalence of
Sc. Mansoni
The estimated sample size
required was 650 individuals;
Barra Mansa City, Rio de Janeiro
State, Brazil
Intervention: diagnostic assays:
ELISA-IgG/ELISA-IgM/IFT-
IgM/qPCR in faeces.
Outcomes: sensitivity/specificity
(95% CI:)
Sensitivity/specificity (95% CI)
KK 13.8% (4–32)/99.8% (99.0–100); ELISA-IgG 66.7%
(48–82)/91.5% (89–94); ELISA-IgM 81.8% (64–93)/82%
(79–85); IFT-IgM 78.8% (61–91)/87.7% (84.8–90); qPCR
in faeces 51.7% (32–71)/92.6% (90–95); qPCR in serum
12.1% (3–28)/99.1% (98–99)
Espirito-Santo
et al., 2014a
[60]
QUADAS-2-12/14
GRADE: very low- to
low-quality evidence
Cross-sectional study
City of Barra Mansa, Rio de
Janeiro State, Brazil, with an
estimated prevalence of 1%
Intervention: diagnostic assays:
ELISA-IgG and ELISA-IgM.
Outcomes: sensitivity/specificity
(95% CI:); PPV, NPV
Sensitivity/specificity (95%CI)
ELISA-IgG 60.0% (15–95) /89.1% (86.2–91.5);
ELISA-IgM 60.0(15–95)/79.2% (75.6–82.5)
PPV/NPV (95%CI):
ELISA-IgG 4.6% (1–13) /99.6% (98–100); ELISA-IgM
2.5% (0.5–7); NPV 99.6% (98.4–100.0)
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Table 1. Cont.
Study Quality Design Population Intervention/Outcomes Results
Espirito-Santo
et al., 2014b
[56]
QUADAS-2-13/14
GRADE: very low- to
low-quality evidence
Cross-sectional
epidemiological survey
7000 inhabitants located in the
outskirts of Barra Mansa, Rio de
Janeiro, Brazil
Intervention: qPCR in serum or
faeces.
Outcomes: sensitivity/specificity
(95% CI:); PPV, NPV
Sensitivity/specificity (95% CI)
qPCR in faeces 80.0% (28–99)/92.4% (90–94); qPCR in
serum 20.0% (0.5–71.6)/98.8 (97–99)
PPV/NPV (95% CI:):
qPCR in faeces 8.0% (2–19)/99.8% (99–100); qPCR in
serum 12.5% (0.3–52.7)/99.3% (98.2–99.8)
Lodh et al.,
2013 [55]
QUADAS-2-12/14
GRADE: very low- to
low-quality evidence
Cross-sectional case study
Filtered urine specimens from
infected and not-infected patients
in Zambia
Intervention: qPCR ELISA IgG in
serum or faeces; filtered Urine PCR.
Outcomes: sensitivity/specificity
(95% CI:); PPV, NPV
Sensitivity/specificity (95%CI)
KK test 57% (45–68)/100% (69–100); CCA rapid test 65%
(56–77)/60% (26–88); PCR 100% (95–100)/100% (69–100)
PPV/NPV:
KK test 100%/23%; CCA rapid test 93%/19%; PCR
100%/100%.
Kinkel et al.,
2012 [54]
QUADAS-2-12/14
GRADE: very low- to
low-quality evidence
Retrospective
comparative diagnostic
study: performance of 8
serological tests for
Schistosoma spp
Serum specimens from infected
patients and those without the
infection in low-prevalence
locations or non-endemic settings
(Germany)
Intervention: serological assays:
IFAT, ELISA-CA, ELISA-AWA,
ELISA-SEA, IHA, ELISA-NovaTec,
ELISA-DRG and ELISA-Viramed.
Outcomes: sensitivity and
specificity (95% CI:)
Sensitivity/specificity-(95% CI):
IFAT 75.7% (58–98)/98.1% (92–99); ELISA-CA 40.5%
(25–59)/95.2% (89–98); ELISA-AWA 54.1%
(37–70)/100% (95.6–100); ELISA-SEA-75.7%
(58–98)/97.1% (91–99); IHA 73.0%
(55.6–85.6)/99.0% (94.0–100); ELISA-NovaTec 64.9%
(47–79)/99 (94–100); ELISA-DRG 78.3% (61.3–89.6)/88.4
(80–94); ELISA-Viramed 67.6% (50–81)/76.9% (67–84).
De Frotas et
al., 2011 [58]
QUADAS-2-12/14
GRADE: very low- to
low-quality evidence
Cross-sectional survey
Stool and serum specimens from
infected and not infected patients,
low-endemic setting in Brazil
Intervention: serological assays,
ELISA IgG
Outcomes: sensitivity and
specificity (95%CI)
Sensitivity/specificity (95% CI):
ELISA-IgG 100% (68–100)/72.9% (67–78).
PPV/NPV (95% CI):
ELISA-IgG 26.0% (18–36) /100% (97–100).
Silveira et al.,
2016 [59]
QUADAS-2-12/14
GRADE: very low- to
low-quality evidence
Evaluation of the CCA
test to diagnose
Sc. mansoni in Minas
Gerais State, Brazil.
Infected individuals in regions
with moderate to high prevalence
Intervention:
CCA-immuno-chromatographic
test.
Outcomes: sensitivity/specificity
(95% CI:)
Sensitivity/specificity (95% CI):
CCA-ICT 68.7% (54–81)/97.6% (87–99)
Beltrame et
al., 2017 [61]
QUADAS-2-12/14
GRADE: very low- to
low-quality evidence
Accuracy of
parasitological and
immunological tests for
the screening of human
schistosomiasis in
immigrants and refugees
from African countries
Frozen serum specimens from
recent African asylum seekers
that were routinely screened for
schistosomiasis in Italy
Intervention: urine CCA;
Bordier-ELISA, Western Blot IgG,
ICT IgG-IgM, microscopy
compared with composite reference
standard.
Outcomes: sensitivity/specificity
(95% CI:)
Sensitivity/specificity (95% CI):
Urine CCA 29% (22–37)/95% (91–97); Bordier-ELISA
71% (63–78)/99.6% (98–100); Western blot IgG 92%
(86–96)/94% (90–97); ICT IgG-IgM 96% (91–99)/83%
(77–87); microscopy 45% (37–54)/100%
Included systematic reviews for diagnostic effectiveness for strongyloidiasis
Campo
Polanco et
al., 2014 [51]
AMSTAR: 11/11
GRADE:
moderate-quality
evidence
Systematic review and
meta-analysis
Individuals with active/chronic
infection
Intervention: Baermann method,
agar plate, direct faecal smear
examination and formol-ether
concentration technique.
Outcome: sensitivity and specificity
(95% CI:)
Sensitivity: Baermann method (72%) with LR+228 and
LR−0.32; APC 89%, LR+341 and LR−0.11; stool
microscopy 21%, LR + 67 and LR−0.67; formol-ether
concentration 48%, LR + 110 and LR−0.59.
Specificity: 100% in all four tests. APC and Baermann
method are best.
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Table 1. Cont.
Study Quality Design Population Intervention/Outcomes Results
Included systematic reviews of diagnostic tests to detect schistosomiasis
Requena-Méndez
et al., [19]
AMSTAR: 7/11
GRADE: low- to
moderate-quality
evidence
Systematic review Individuals with active/chronicinfection
Intervention: Baermann method,
agar plate, direct faecal smear
examination and formol-ether
concentration technique,
serological techniques.
Outcome: sensitivity and specificity
(95% CI:)
No meta-analysis was undertaken. Sensitivity and
specificity of different techniques were individually
reported.
Included primary studies for diagnostic effectiveness for strongyloidiasis
Bisofi et al.,
2014 [62]
QUADAS-2: 13/14
GRADE: low-quality
evidence
Retrospective
comparative diagnostic
study to evaluate the
performance of 5 tests for
St. stercoralis.
Serum specimens from subjects
with St. stercoralis; healthy people
and patients with previous
exposure
Intervention: IFAT, NIE-LIPS
NIE-ELISA, IVD-ELISA- and
Bordier-ELISA
Outcome: sensitivity and specificity
(95% CI:)
Sensitivity/specificity (95% CI):
NIE-ELISA 75.4% (67–83)/94.8% (91–99); NIE-LIPS
85.1% (78–92)/100% (100–100); IFAT 93.9%
(89–98)/92.2% (87–97); IVD-ELISA 91.2% (86–96)/99.1%
(97.4–100.0); Bordier-ELISA 89.5% (84–95) 98.3%
(96–100).
Rascoe et al.,
2015 [63]
QUADAS-2: 10/14
GRADE: low-quality
evidence
Retrospective
comparative diagnostic
study of 5 tests for the
follow-up of patients
infected with St. stercoralis
Serum samples positive for St.
stercoralis and negative samples
from United States residents with
no history of foreign travel
Intervention: Ss-NIE-1 ELISA,
Ss-NIE-1 Luminex.
Outcome: sensitivity and specificity
(95% CI:)
Sensitivity/specificity (95% CI):
SS-NIE-1 ELISA 95% (92–97)/93% (90–96); Ss-NIE-1
Luminex 93% (88–96)/95% (93–97).
The inter-assay coefficient of variation was determined
to be 22% for the low-positive control serum and 10%
for the medium-positive control serum.
Knopp et al.,
2014 [64]
QUADAS-2: 11/14
GRADE: low-quality
evidence
International standard
randomised controlled
trial
Children and adults residing in
rural villages in the Baga moyo
District, Tanzania (endemic areas)
Intervention: Real-time PCR,
FLOTAC technique, KK method.
Outcome: sensitivity and specificity
(95% CI:)
Sensitivity/specificity (95% CI):
PCR + pseudo-standard PCR 17.4 (8–31)/3.9 (89–97);
Baermann + pseudo-standard 47 (23–72)/78.4 (72 -84);
PCR + multiple gold standard 30.9 (19.1–44.8)/100
(100–100); Baermann + multiple gold standard 83.6
(71.2–92.2)/100 (100–100)
AWA: adult worm antigen; AMSTAR: a tool for assessing the methodological quality of systematic reviews; APC: agar plate culture; CA: Cercarial antigen; CCA: circulatory cathodic
antigen; CI: confidence interval; DOR: diagnostic odds ratio; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; ELISA: enzyme-linked immunosorbent
assay; FLOTAC: novel multivalent faecal egg count method; ICT: Immuno chromatographic test; IFAT: indirect fluorescent antibody technique; IHA: indirect haemagglutination: In
Vitro Diagnostic kit; KK: Kato–Katz method; LIPS: luciferase immunoprecipitation system; LR+: positive likelihood ratio; LR−: negative likelihood ratio; NIE: a 31-kDa recombinant
antigen; NovaTec: NovaTec Immundiagnostica, Dietzenbach, Germany; NPV: negative predictive value; POC: point-of-care; qPCR: quantitative PCR (real-time polymerase chain reaction);
PPV: positive predictive value; RCT: randomised controlled trial; SEA: soluble egg antigen; Ss-NIE-1: a luciferase tagged recombinant protein of St. stercoralis for IgG and IgG4 specific
antibodies; QUADAS-2: a tool for the quality assessment of diagnostic accuracy studies; Viramed®: Viramed Biotech, Planegg, Germany).
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Table 2. Characteristics of included studies about efficacy of treatment for schistosomiasis and strongyloidiasis, 1993–2016.
Study Quality Design Population Intervention/Outcomes Results
Treatment efficacy of anti-Schistosoma drugs
Kramer et al.,
2014 [48]
AMSTAR: 11/11
Data in study:
GRADE: high-quality
evidence
Systematic review,
fixed effects meta-analysis;
Embase, MEDLINE (1966
to 2014), LILACS,
Cochrane library,
Cochrane infectious
disease (1980–2014)
School-aged and young adults:
6–20 years (16 trials); 2–23 years
(5 trials); Adults (2 trials).
Participants setting: Rural areas
in 15 sub-Saharan African
countries; an urban setting in
Saudi Arabia
Interventions: drugs used to treat
urinary schistosomiasis: praziquantel,
metrifonate, artesunate and/or in
combination
Outcome: parasitological cure or
failure at 4 weeks; % egg reduction rate
at 4 weeks
Praziquantel (single dose 40 mg/kg), egg reduction (60%)
in urine achieved in 4–8 weeks (38 per 100 (95% CI: 26–54).
Treatment failure: RR 0.42, (95% CI: 0.29–0.59), 864
participants, 7 trials
Metrifonate (single dose 10 mg/kg) reduced egg excretion
only marginally in comparison to placebo (RR 0.63, 95% CI:
0.54 to 0.73) 210 participants, 1 trial, at 8 months
Danso-Appiah
et al., 2013 [47]
AMSTAR: 11/11
Data in study:
GRADE: low- to
moderate-quality
evidence
Systematic review and
meta-narrative of RCTs,
RTCs of anti-Schistosoma
drugs
Trials conducted in Africa
(n = 36), South America (n = 15;
all in Brazil) and the Middle
East (n = 1).
52 trials enrolling 10,269
participants in endemic areas
Intervention: praziquantel 40 mg/kg,
oxamniquine 40 mg/kg
Praziquantel (single dose 40 mg/kg) vs. placebo: reduced
parasitological treatment failure at 1 month (69/100; RR =
3.13, 2 trials, 414 participants).
Praziquantel (single dose 30 mg/kg): RR = 1.52, 3 trials, 521
participants.
Higher doses: no significant difference.
Oxamniquine (single dose 40 mg/kg) vs. Placebo: reduced
parasitological treatment failure at 3 months in 2 trials
(68/100; RR = 8.74).
Pérez del Villar
et al., 2012 [49]
AMSTAR: 11/11
Data in study:
not reported.
GRADE:
Moderate-quality
evidence
Quantitative systematic
review and meta-analysis
Healthy villagers who live in
areas in Africa endemic for
Sc. haematobium and Sc. mansoni
and in China for Sc. Japonicum
Intervention: prophylactic effect of
artesunate or artemether vs. placebo
against Sc. haematobium, Sc. mansoni
and Sc. japonica infections.
Outcomes: parasitological cure rate at
3–8 weeks; infection rate at 3–4 weeks
after treatment.
Artesunate treatment (single dose: significantly lower cure
rates than with praziquantel.
Combined therapy of artesunate plus
sulfadoxine-pyrimethamine: significantly less effective than
praziquantel treatment
Combination of artemisinin derivatives and praziquantel:
higher cure rate than praziquantel monotherapy
Artesunate or artemether: significantly better than a
placebo.
Treatment efficacy of drugs for strongyloidiasis
Henriquez-
Camacho et al.,
2016 [52]
AMSTAR: 11/11
GRADE:
Moderate-quality
evidence
Systematic review of
RCTs, controlled or
uncontrolled
interventional studies.
Individuals with chronic
infections of St. stercoralis;
Immuno-competent patients.
All ages
Intervention: ivermectin
(single/double dose) vs. albendazole
or thiabendazole.
Outcome: elimination of infection;
parasitological cure (>2 negative stool
samples, 5 weeks).
Ivermectin (single/double dose) vs. albendazole:
parasitological cure was higher with ivermectin, 84/100 vs.
48/100 ivermectin (RR = 1.79). Ivermectin vs.
thiabendazole: little or no difference in parasitological cure,
74/100 vs. 68/100), but adverse events were less common
with ivermectin (RR = 0.31) than albendazole. No serious
adverse events or death reported
AMSTAR: a tool for assessing the methodological quality of systematic reviews; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; LILACS: Latin American
Literature in Health Sciences; RCT: randomized clinical trial; RR: Relative Risk.
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Table 3. Characteristics of included studies on cost-effectiveness of screening and treatment of schistosomiasis and strongyloidiasis, 1993–2016.
Study Quality Design Population Intervention/Outcomes Results
Libman et al.,
1993 [70] NA
Retrospective-cross-sectional
study with cost analysis
Cohort of individuals returning
from the tropics and screened
in a Canadian clinic 1981–1987
Costs in 1988 CAD
Stool examination + eosinophil count +
serological studies for filariasis and
schistosomiasis (gold standard); vs.
stool examination + eosinophil count;
vs. stool examination alone; vs. stool
examination + serological studies; vs.
eosinophil counts only
Outcome: difference in cost or resource
use/cost effectiveness
Difference in resource use/costs: high-/low-prevalence
locations
Costs per case of schistosomiasis and/or
strongyloidiasis diagnosed for each strategy: (i)
CAN$4674 [€3693]; (ii) CAN$6111 [€4829]; (iii)
CAN$4788 [€3783]; (iv) CAN$3737 [€2953]; (v)
CAN$3307 [€2613]
Cost-effectiveness (ICER or INB): no ICER calculated.
Study did not include a decision analytic model
Muennig et al.,
1999 [66] NA Decision analytic model
Large immigrant populations in
which St. stercoralis is not
endemic (one third of the
sample population was from
the state of New York)
Costs in 1997 USD
No preventive intervention (watchful
waiting) vs. universal screening vs.
presumptive treatment with
albendazole
Outcome: difference in cost or resource
use/cost effectiveness (ICER or INB)
per DALY averted
Difference in resource use/costs: gross costs: USD
11,086,181 [€7,228,785] for no intervention, USD
7,290,624 [€40,203,726] per year for treatment with
albendazole, USD 40,547,651 [€40,203,726] for universal
screening
Cost-effectiveness (ICER or INB): treatment with
albendazole was cost saving compared with no
intervention, universal screening had ICER of USD
159,236/DALY [€157,885/DALY] averted
Muennig et al.,
2004 [67] NA
Decision analytic model
(Markov)
California and New York, two
states with large immigrant
populations in which St.
stercoralis is not endemic
Costs in 2000 USD
Intervention: no intervention (watchful
waiting) vs. 3 or 5 days of albendazole
vs. eosinophil screening vs. ivermectin
Outcome: difference in cost or resource
use/cost effectiveness (ICER or INB)
Difference in resource use/costs: costs per person: no
intervention USD 1666 [€1611], albendazole 3 days USD
1674 [€1618], albendazole 5 days USD 1680 [€1624],
screening USD 1684 [€1628], ivermectin USD 1688
[€1632]
Cost-effectiveness (ICER or INB): ICERs varied based
on prevalence: albendazole USD 155–1584/QALY
gained [€150–1531], albendazole 5 days USD
314–3175/QALY gained [€304-3069], ivermectin USD
848–8514/QALY gained [€820-8231]. Eosinophil was
documented among all prevalence groups
King et al.,
2011 [65] AMSTAR
Systematic review of efficacy of
schistosomiasis treatment with
praziquantel (by dose), with a
Markov model estimating
cost-effectiveness of various
dosing strategies
Non-migrants in endemic
setting; population-based or
sub-population-based (e.g.,
schools) drug treatment of
Sc. haematobium or Sc. Mansoni.
Costs in 2002 & 2008 USD
Intervention: No treatment vs. single
dose of praziquantel per annual
treatment vs. double dose
Outcome: difference in cost or resource
use/cost effectiveness (ICER or INB)
Difference in resource use/costs: single dose lifetime
cost: USD 23 [€19] per person; double dose: USD 46
[€35] per person.
Cost-effectiveness (ICER or INB): single dose: ICER of
USD 48 [€39] and USD 46 [€37] per QALY gained for Sc.
mansoni and Sc. haematobium, respectively, compared
with no treatment; double dose: ICERs of USD 291
[€236] and USD 433 [€351] per QALY gained
respectively compared with single dose
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Table 3. Cont.
Study Quality Design Population Intervention/Outcomes Results
Worrell et al.,
2015 [69] NA Cost analysis study
Cohort of children in Kenya
assessed 2010–2011.
Non-migrant settings.
Costs in 2010 USD
Intervention: single KK (stool
examination) vs. triplicate KK vs. POC
CCA (urine dipstick)
Outcome: difference in cost or resource
use/cost effectiveness (ICER or INB)
Difference in resource use/costs: total costs per test:
single KK USD 6.89 [€5], triplicate KK USD 17.54 [€14],
POC CCA USD 7.26 [€6]
Cost-effectiveness (ICER or INB): no ICER calculated,
this was not a decision analysis study.
Maskery et al.,
2016 [68] NA
Cost analysis study; Markov
model: discount rate of 3% over
60-year time horizon; costs in
2013 USD
Average annual cohort of
27,700 Asian refugees based on
Department of
Homeland Security data for
2002–2011, primarily from
south-east Asia and the Middle
East
Intervention: no screening or treatment
vs. overseas albendazole and
ivermectin treatment vs. domestic
screening and treatment vs. overseas
albendazole and domestic screening
for strongyloidiasis. Outcome:
difference in cost or resource use/cost
effectiveness (ICER or INB)
Difference in resource use/costs, total costs per migrant
(strongyloidiasis.): no treatment USD 5.99 [€5], overseas
albendazole and ivermectin USD 15.12 [€12], domestic
screening and treatment USD 138.36 [€108], overseas
albendazole and domestic screening for Strongyloides
infection USD 78.79 [€61].
Cost-effectiveness: ICERs per QALY gained: USD 2219
for “overseas albendazole and ivermectin”, USD 32,706
[€25,422] for domestic screening and treatment, USD
18,167 [€14,121] for overseas albendazole followed by
domestic screening for strongyloidiasis. All vs. no
screening or treatment [€1723]
AMSTAR: A measurement tool to assess systematic reviews; CAD: Canadian dollars; CCA: circulatory cathodic antigen; GRADE: Grading of Recommendations, Assessment, Development
and Evaluation; ICER: incremental cost-effectiveness ratio, INB: incremental net benefit; NA: Not Applicable KK: Kato–Katz; POC: point-of-care; USD: United States dollars.
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3.1. Screening: Diagnostic Test Accuracy for Schistosomiasis
We assessed diagnostic and screening tools for Schistosoma spp. in five included systematic
reviews [44–46,50,53] and eight individual studies [54–61]. The best performing tests were included
in the GRADE summary of finding on diagnostic tools for screening schistosomiasis (Table 4 and
Figure 5).
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3.1.1. Schistosoma Mansoni
A meta-analysis reported estimated sensitivity and specificity values of 89% (95% CI: 86–92) and
55% (95% CI: 46–55) respectively, for the urinary circulating cathodic antigen (CCA) assay that detects
Sc. mansoni in endemic areas [44]. Another urinary CCA test for Sc. mansoni [53] reported sensitivity
and specificity values of 90% (95% CI: 84–94) and 56% (95% CI: 39–71), respectively compared with
the duplicate Kato–Katz (KK) test (moderate-quality evidence) (Table 4). From the included primary
studies, PCR assay in urine was the best-performing diagnostic test for Sc. mansoni with a sensitivity of
100% (95% CI: 95–100) compared with the CCA test—65% (95% CI: 56–77) and KK test—57% (95%
CI: 46–68) [55] (very low-quality evidence); the specificity of PCR assay in urine was 100% (95% CI:
69–100) (Table 4) [55]. Espírito-Santo et al. reported sensitivity and specificity of 80% (95% CI: 28–99)
and 92.4% (95% CI: 90–94), respectively for quantitative PCR (qPCR) in faeces compared with the KK
test (not included in the GRADE Summary of findings) [56].
In low-endemic settings, the best-performing diagnostic test was the IgM-ELISA assay
with sensitivity and specificity values of, respectively, 82% (95% CI: 64–93) and 82% (95% CI:
79–85)-low-quality evidence (Table 1) [57]. In another study, the ELISA-DRG kit showed the best
accuracy with sensitivity and specificity values of, respectively, 78% (95% CI: 61–90) and 95% (95% CI:
89–98) (Table 4) [54]. In a recent study on the accuracy of different screening tests for schistosomiasis
in African migrants, the immuno chromatographic test (ICT) IgG-IgM showed the best accuracy, with
sensitivity and specificity values of 96% (95% CI: 91–99) and 83% (95% CI: 77–87) (Table 4) [61]. In all
the individual studies, the certainty of evidence was very low to low.
3.1.2. Schistosoma Haematobium
The urine heme dipsticks for the diagnosis of Sc. haematobium showed a mean sensitivity and
specificity of 81% (95% CI: 73–83) and 89% (95% CI: 87–92), respectively, an wer more accurate
in high-prevalence than in low-prev lence settings -low-quality evidence (Table 4) [45]. Similarly,
Oc odo et al. reported sensitivity and specificity values of 75% (95% CI: 71–79) and 87% (95% CI:
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84–90)-low-quality evidence (Table 1) [44]. Furthermore, a meta-analysis on the diagnostic efficiency
of questionnaire screening for schistosomiasis reported sensitivity and specificity values of 85% (95%
CI: 84–86) and 94% (95% CI: 94–94) for Sc. haematobium infections (low-quality evidence) (Table 4) [50].
Kinkel et al. evaluated the accuracy of antibody-detection tests for diagnosis of imported
Sc. haematobium [54]. The indirect haemagglutination (IHA) test with a sensitivity of 73% (95% CI:
56–86) and specificity of 99% (95% CI: 94–100) and the ELISA-DRG with a sensitivity of 78% (95% CI:
61–90) and specificity of 95% (95% CI: 89–98) demonstrated the best accuracy (certainty of evidence
low) (Table 4) [54]. In another study, the ICT IgG-IgM test showed the best accuracy with sensitivity of
96% (95% CI: 91–99) and specificity of 83% (95% CI: 77–87) (Table 4) [61].
3.1.3. Schistosoma Japonicum
In a meta-analysis of the accuracy of antibody detection of Sc. japonicum infection in humans,
pooled sensitivities and specificities were 76% (95% CI: 74–77) and 73% (95% CI: 72–74) for the IHA
test and 85% (95% CI: 83–87) and 50% (95% CI: 49–52) for ELISA (Table 4) [46].
The evidence also suggests that accuracy of diagnostic tests for schistosomiasis depends
on pre-test prevalence (Table 5). As prevalence increased (from 2.5% to 30%), the estimated
number of false-positives per 1000 migrants tested decreased with all tests—from 47 to 34
(Sc. haematobium/Sc. mansoni) [54], 58 to 42 (Sc. haematobium) [44], 107 to 77 (Sc. Haematobium) [45] and
166 to 119—(Sc. haematobium/Sc. mansoni) [61] per 1000 for ELISA-DRG, questionnaire screening, urine
heme dipsticks and ICT IgG-IgM, respectively. The estimated false-negative tests were between 0–6 and
0–73 per 1000 at 2.5% and 30% prevalence for all the tests. At 2.5% pre-test prevalence, the proportion
of correctly diagnosed schistosomiasis infections in migrant populations was 100% for the urine PCR
assay, 96% for the ICT IgG-IgM test, 90% for the urine POC CCA, 85% for the questionnaire screening
and 84.9% for Sc. japonicum ELISA (Table 5).
3.2. Screening: Diagnostic Test Accuracy for Strongyloidiasis
We assessed diagnostic and screening tools for St. stercoralis in two included systematic
reviews [19,51] and three individual studies (Tables 1 and 6) [62–64].
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Table 4. GRADE summary of findings on diagnostic tools for screening schistosomiasis, 1993–2017.
Index Test at Median Test
Prevalence in Study *
Sensitivity
(95% CI)
Specificity
(95% CI)
Post-Test
Probability of a
Positive Result
(95% CI)
Post-Test
Probability of a
Negative Result
(95% CI)
Number of
Studies/
Participants
Certainty of
Evidence
(GRADE)
Reference Standard
PCR assay (filtered urine) at 89%
prevalence—Sc. mansoni [55] 1.00 (0.95–1.00) 1.00 (0.69–1.00) 100% (96–100) 0% (37–0) 1/89 Very Low
a,b,c KK test—duplicate smears
Urine POC CCA test at 36%
prevalence—Sc. mansoni [44] 0.89 (0.86–0.92) 0.55 (0.46–0. 65) 53% (47–60) 10% (15–7) 15/6091 Very Low
a,b,c Stool microscopy
Urine POC CCA test at 30%
prevalence—Sc. mansoni [53] 0.90 (0.84–0.94)
d 0.56 (0.39–0.71) d 47% (37–58) 7% (15–3) 7/4584 Moderate a,b KK test
Questionnaire screening 30%
prevalence—Sc. haematobium [50] 0.85 (0.84–0.86)
d 0.94 (0.94–0.94) d 86% (86–86) 6% (7–6) 12/41,412 Low c,e Urine filtration/microscopy
ELISA-DRG (commercial kit) at
26% prevalence—All cases [54] 0.78 (0.61–0.90) 0.88 (0.80–0.94) 85% (65–95) 7% (13–4) 1/37 Very Low
c,e,f Stool/urine microscopy
Urine heme dipstick at 27%
prevalence—Sc. haematobium [45] 0.81 (0.73–0.83)
d 0.89 (0.87–0.92) d 73% (67–79) 7% (10–6) 98/126,119 Low a,f,g Urine microscopy
ELISA at 24% prevalence—Sc.
japonicum [46] 0.85 (0.83–0.87) 0.50 (0.49–0.52) 35% (34–36) 9% (10–7) 10/9014 Low
a,f,g KK and Miracidium hatching test
IHA at 12% prevalence—Sc.
japonicum [46] 0.76 (0.72–0.74)
d 0.73 (0.72–0.74) d 28% (26–28) 4% (5–5) 15/23,411 Low a,b KK and Miracidium hatching test
ICT IgG-IgM test at 17%
prevalence Sc. mansoni and
Sc. haematobium [61]
0.96 (0. 91–0.99) 0.83 (0.77–0.87) 13% (9–16) 0% (0–0) 1/373 Low b,c
Stool/urine microscopy/
composite standard.
Population: patients with schistosomiasis or stored sera; Settings: high-/low-endemic settings; Target condition: Schistosoma spp. Infections. GRADE: Grading of Recommendations,
Assessment, Development and Evaluation. Tests—CCA: circulating cathodic antigen; CI: confidence interval; DRG: DRG Instruments, Marburg, Germany; ELISA: enzyme-linked
immunosorbent assay; IHA: indirect haemagglutination; KK: Kato–Katz; POC: point-of-care. * Post-test probability of test was calculated at median test prevalence obtained from
individual studies.
a Heterogeneity across similar studies because of several factors; downgraded because of serious inconsistency.
b Use of intermediate or surrogate outcomes rather than health outcomes, hence a source of serious indirectness.
c Single study design, not a randomised control trial.
d Sensitivity and specificity values obtained from multiple-field study.
e Use of indirect comparisons; sample population not migrants, another source of indirectness.
f Very low-quality of evidence (downgraded by 1) because of serious indirectness.
g Studies were insufficient to provide summary estimates for CAA tests.
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Table 5. Accuracy of diagnostic tools for schistosomiasis at different pre-test prevalence levels, January 2010–February 2017.
Index Test True PositivesPre-Test Probability *
False Positives
Pre-Test Probability *
True Negative
Pre-Test Probability *
False Negative
Pre-Test Probability
% Infected
Correctly
DiagnosedTest % Prevalence a 2.5% 10% 30% 2.5% 10% 30% 2.5% 10% 30% 2.5% 10% 30%
PCR assay (filtered urine)—Sc. mansoni [55] 25 100 300 0 0 0 975 900 700 0 0 0 100%
ICT IgG-IgM test—Sc. haematobium/Sc. mansoni [61] 24 96 288 166 153 119 809 747 581 1 4 12 96%
Urine POC CCA test—Sc. mansoni [53] 23 90 270 429 396 308 546 504 392 2 10 30 90%
Questionnaire screening—Sc. haematobium [50] 21 85 255 58 54 42 917 846 658 4 15 45 85%
ELISA-DRG (commercial kit)—Sc.
haematobuim/Sc. mansoni [54] 20 78 235 47 43 34 928 857 666 5 22 65 78.3%
Urine heme dipstick—Sc. haematobium infections [45] 20 81 243 107 99 77 868 801 623 5 19 57 81.0%
ELISA—Sc. japonicum [46] 21 85 255 484 446 347 491 454 353 4 15 45 84.9%
IHA—Sc. japonicum [46] 19 76 227 263 243 189 712 657 511 6 24 73 75.6%
a Different pre-test prevalence or probability of having schistosomiasis in an at-risk population. * Data reported as effect per 1000 migrants tested. Tests: DRG: DRG Instruments, Marburg,
Germany; ELISA: enzyme-linked immunosorbent assay; ICT: Immuno chromatographic test; IHA: Indirect haemagglutination; PCR: Polymerase chain reaction assay; POC: Point of care.
Table 6. GRADE summary of findings on diagnostic tools for screening strongyloidiasis, January 1993–February 2017.
Index Test—at 10% Prevalence * Sensitivity(95% CI)
Specificity
(95% CI)
Post-Test
Probability of a
Positive Result
(95% CI)
Post-Test
Probability of a
Negative Result
(95% CI)
Number of
Studies/
Participants
Certainty of
Evidence
(GRADE)
Reference Standard
Baermann method [51] 0.72 (0.67–0.76) a 1.00 (1.00–1.00) a 100% (100–100) 3% (4–3) 9/2459 Moderate b,c Combination of diagnostic tests
Agar plate—10% prevalence [51] 0.89 (0.86–0.92) a 1.00 (1.00–1.00) a 100% (100–100) 1% (2–1) 10/3563 Moderate b,c Combination of diagnostic tests
NIE LIPS [62] d 0.85 (0.79–0.92) 0.95 (0.93–0.98) 65% (56–84) 2% (2–1) 1/399 Low e,f,g Stool microscopy or culture
IVD ELISA—commercial test [62] 0.92 (0.87–0.97) 0.97 (0.96–0.99) 77% (71–92) 1% (1–0) 1/399 Low e,f,h Stool microscopy
IFAT [62] 0.94 (0.90–0.98) 0.87 (0.83–0.91) 45% (37–55) 1% (1–0) 1/399 Low e,f,h Stool microscopy and culture
Bordier-ELISA—commercial kit [62] 0.91 (0.86–0.96) 0.94 (0.91–0.96) 63% (52–77) 1% (2–0) 1/193 Low e,f,h Kato–Katz, Flotac, and Baermann method
SS-NIE-1 ELISA [63] 0.95 (0.92–0.97) 0.93 (0.90–0.96) 60% (71–73%) 1% (1–0) 1/583 Low f,g,i Stool microscopy and culture
Notes: Population: patients with strongyloidiasis or sera infected with St. stercoralis; Settings: low-/high-endemic areas; Target condition: strongyloidiasis (test prevalence 10%).
Cost effectiveness: serological testing may be cost-effective relative to stool and eosinophil testing for both strongyloidiasis and schistosomiasis, because of superior test performance
characteristics. Tests: ELISA: enzyme-linked immunosorbent assay; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; IFAT: indirect fluorescent antibody
technique; IVD: Invitro diagnostic test; LIPS: luciferase immunoprecipitation system; NIE: a 31-kDa recombinant antigen from St. stercoralis. * Post-test probability of test was calculated at
10% prevalence for all the tests.
a Sensitivity and specificity values obtained from a multiple-field study.
b Evidence was downgraded because of serious inconsistencies and heterogeneity.
c Heterogeneity between studies; use of intermediate or surrogate outcomes rather than health outcomes.
d Test result with a primary standard.
e Absence of a reliable gold standard for diagnosis of S. stercoralis infection. The review did not describe the specific gold standard used in the included studies for each test.
f Single study design.
g Samples were classified according to a composite reference standard, a procedure suggested for evaluation of diagnostic tests when there is no gold standard.
h Use of intermediate or surrogate outcomes rather than health outcomes.
i The inter-assay coefficient of variation was determined to be 22% for the low-positive control serum and 10% for the medium-positive control serum.
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The best conventional diagnostic tools for St. stercoralis have been agar plate culture with a
sensitivity and specificity of 89% (95% CI: 86–92) and 100% (95% CI: 100–100) respectively, and the
Baermann method with a sensitivity and specificity of 72% (95% CI: 67–76) and 100% (95% CI: 100–100)
respectively (moderate certainty of evidence) [51]. Knopps et al. reported a much lower sensitivity
value of 31% (95% CI: 19.1–44.8) for PCR in stools compared with a combination of stool-based methods
as the gold standard; specificity was 100% (95% CI: 100–100) [64].
Serological antibody detection methods have demonstrated greater sensitivity compared with
classical parasitological techniques [19]. Bisoffi et al. reported the accuracy of five serological tests
for detection of strongyloidiasis [62]. The sensitivity and specificity values were: 85% (95% CI:
79–92) and 100% (95% CI: 100–100) for the luciferase-immunoprecipitation system (LIPS) using 31-kD
recombinants antigen from St. stercoralis (NIE); 75% (95% CI: 66–83) and 95% (95% CI: 91–99) for the
NIE-ELISA (using the same antigen); 91% (95% CI: 86–96) and 99% (95% CI: 97–100) for the IVD-ELISA;
90% (95% CI: 84–95) and 98% (95% CI: 96–100) for the Bordier-ELISA; and 94% (95% CI: 90–98) and 92%
(95% CI: 87–97) for the indirect fluorescent antibody technique (IFAT) (low certainty of evidence) [62]
(Figure 6). Rascoe et al. reported comparable values for two new recombinant antigens in antibody
detection assays: SS-NIE-1 ELISA with sensitivity of 95% (95% CI: 92–97) and specificity of 93% (95%
CI: 90–96), and Ss-NIE-1 Luminex with sensitivity of 93% (95% CI: 86–96) and specificity of 95%
(95% CI: 93–97) (Table 6) [63].
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Figure 6. Scatter plot of sensitivity versus specificity values of the Index diagnostic tools for
screening strongyloidiasis.
As with schistosomiasis, estimates of false-positive tests per 1000 tested decreased with increasing
pre-test prevalence, from 29 to 21, 58 to 42 and 68 to 49 for IVD-ELISA, Bordier-ELISA and SS-NIE-1
ELISA assays, respectively [62,63]. The estimated number of false-positive tests for the Baermann and
Agar plate methods was 0 at all pre-test prevalence levels. Lower numbers of false-negatives were
estimated for all the serological tests, for example, 1 and 15, and 2 and 24, per 1000 tests for SS-NIE-1
and IVD-ELISA at 2.5% and 30% prevalence levels compared with 3 and 33, and 7 and 84, per 1000
for the Agar plate and Baermann methods. At 2.5% pre-test prevalence, the proportion of correctly
diagnosed Strongyloides infections in migrant populations was 95% for the SS-NIE-1 ELISA, 93.8% for
IFAT, 92% for IVD-ELISA and 90.7% for Bordier-ELISA, compared with 72% and 89% for the Baermann
and Agar plate methods (Table 7).
3.3. Treatment Efficacy: Schistosomiasis and Strongyloidiasis
We evaluated four included systematic reviews on treatment of schistosomiasis and
strongyloidiasis (Tables 8 and 9) [47–49,52]. In a Cochrane review, the efficacy of praziquantel (single
40 mg/kg dose) showed much lower parasitological failure in urine (<53%) at 1 to 2 months (RR = 0.42;
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95% CI: 0.29–0.58) compared with placebo [48]. The proportion of people cured with praziquantel
varied substantially between trials, from 22.5% to 83.3%, but was higher than 60% in five of the seven
trials [48]. Similarly, in another Cochrane review, parasitological cure rate for Sc. mansoni infection at
one month with praziquantel (single 40 mg/kg dose) varied substantially across studies, ranging from
52% to 92% in Brazil in 2006 and 2007, for example parasitological cure 66% more in intervention group
compared with placebo (RR 3.13; 95% CI: 1.03–9.53) (Table 8) [47]. Pérez del Villar et al. compared the
efficacy of praziquantel and artemisinin derivatives and reported that artesunate showed significantly
lower cure rates than praziquantel 30% vs. 61% (RR 0.49 (0.28–0.75)) [49]. Artemeter monotherapy
(6mg/kg single dose) reduced Sc. Japonicum infection rates in patients (RR = 0.25; 95% CI: 0.16–0.40).
However, a combination of artemisinin derivatives plus praziquantel showed higher cure rates than
praziquantel monotherapy (RR = 1.25; 95% CI: 1.09–1.37) in areas with intense transmission (moderate
certainty of evidence) (Table 8) [49]. No significant adverse events were reported.
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Table 7. Accuracy of diagnostic tools for strongyloidiasis at different pre-test prevalence levels, 2012–February 2017.
Index tests True-PositivesPre-Test Probability a
False-Positives
Pre-Test Probability a
True-Negatives
Pre-Test Probability a
False-Negatives
Pre-Test Probability a % Infected Correctly Diagnosed
Test % Prevalence b 2.5% 10% 30% 2.5% 10% 30% 2.5% 10% 30% 2.5% 10% 30%
Baermann method [51] 18 72 216 0 0 0 975 900 700 7 28 84 72%
Agar plate [51] 22 89 267 0 0 0 975 900 700 3 11 33 89%
NIE-LIPS [62] 21 85 255 49 45 35 926 855 665 4 15 45 85.1%
IVD-ELISA (commercial test) [62] 23 92 276 29 27 21 946 873 679 2 8 24 92%
IFAT [62] 23 94 282 127 117 91 848 783 609 2 6 18 93.8%
Bordier-ELISA (commercial kit) [62] 23 91 272 58 54 42 917 846 658 2 9 28 90.7%
SS-NIE-1 ELISA [63] 24 95 285 68 63 49 907 837 651 1 5 15 95%
ELISA: enzyme-linked immunosorbent assay; IFAT: indirect fluorescent antibody technique; IVD: Invitro diagnostic test; LIPS: luciferase immunoprecipitation system; NIE: 31-kDa
recombinant antigen from St. stercoralis.
a Data reported as effect per 1000 migrants tested.
b pre-test prevalence or probability of having schistosomiasis in an at-risk population.
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Table 8. GRADE summary of findings of different schistosomiasis treatments vs. placebo, 2010–2016.
Outcomes
Anticipated Absolute Effects a
(95% CI) Relative Chance of Cure
(95% CI)
Number of
Participants/Studies
Certainty of the
Evidence (GRADE)Risk with Placebo per
1000
Cure with Intervention
Drug
Parasitological failure at 1 to 2 months (praziquantel 40
mg/kg single dose) [48] 908 381 (263–562) RR 0.42 (0.29 to 0.58) 864/7 RCTs High
Parasitological cure at 1 month b—Sc. mansoni infections
(praziquantel 40 mg/kg single dose) [47]
337 1000 (347–1000) RR 3.13 (1.03–9.53) 414/2 RCTs Moderate c
Microhaematuria at 8 weeks (praziquantel 40 mg/kg
single dose) [48] 281 149 (93–236) RR 0.53 (0.33–0.84) 119/1 RCT Low
d,e,f
Infection rate of Sc. japonicum (artemether monotherapy 6
mg/kg) [49] 175 44 (28–70) RR 0.25 (0.16–0.40) 8051/13 RCTs Moderate
c
Parasitological cure rate of Schistosoma species.
(Artesunate—monotherapy (4 mg/kg daily for three
consecutive days)) [49]
615 * 302 (172–459) RR 0.49 (0.28–0.75) 800/7 RCTS Moderate c
Adverse events, minor (praziquantel 40 mg/kg single
dose) [49] None None Not estimable 1591/9 RCTs Low
d
CI: confidence interval; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; RR: risk ratio; RTC: randomized controlled trial. * praziquantel 40 mg/kg once.
a The risk in the intervention group per 1000 persons treated (95% CI) was based on the assumed risk in the comparison group and the relative effect of the intervention (and its
95% CI).
b Treatment of only Sc. mansoni infections reported.
c Downgraded by 1 for indirectness: only two trials from limited settings evaluated this comparison.
d The trial was under-powered; downgraded by 1.
e Only a single trial reported this outcome.
f Publication bias was unclear.
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Table 9. GRADE summary of findings on ivermectin (200 mg/kg) vs. albendazole or thiabendazole for the treatment of strongyloidiasis, and certainty of evidence on
treatment efficacy, benefits and harms, 2010–2016.
Outcomes
Anticipated Absolute Effects
(95% CI)
Relative Chance of Cure
(95% CI) b
Number of
Participants/Studies
Certainty of the
Evidence (GRADE)Cure with Comparator
Drug per 1000 a
Cure with Intervention
Drug—Ivermectin
(200 mg/kg) b
Cure overall assessed at 5 weeks—albendazole [52] 480 840(720–980)
RR 1.79
(1.55–2.08) 478/4 RCTs Moderate
d
Adverse events assessed at 5 weeks—albendazole [52] 260 210(150–290)
RR 0.80
(0.59–1.09) 518/4 RCTs Low
c,g
Cure overall assessed at 11 weeks—thiabendazole [52] 690 740(660–820)
RR 1.07
(0.96–1.20) 467/3 RCTs Moderate
e
Adverse events assessed at 11 weeks—thiabendazole [52] 730 230(150–360)
RR 0.31
(0.20–0.50) 507/3 RCTs Moderate
f
PICO—Patient or population: sersons with Strongyloides stercoralis infection; Setting: south-east-Asia, America and Europe; Intervention: ivermectin; Comparison: albendazole and
thiabendazole. CI: confidence interval; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; RR: risk ratio; RTC: randomized controlled trial.
a Albendazole or thiabendazole.
b The risk in the intervention group per 1000 persons treated (95% CI) was based on the assumed risk in the comparison group and the relative effect of the intervention (and its
95% CI).
c No method of allocation concealment in two trials and no method of allocation described.
d Two trials did not conceal allocation and no method of allocation was described.
e Two trials did not conceal allocation and no method of allocation was described in one trial.
f Two trials did not conceal allocation and no method of allocation was described.
g Wide range of estimates in three trials could include substantive fewer events.
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Only one systematic review was included which addressed the efficacy of ivermectin
vs. albendazole or thiabendazole for treating chronic strongyloidiasis infection (Table 9) [52].
Parasitological cure determined with both serological and conventional techniques was higher with
ivermectin (single-/double-dose) treatment than with albendazole 84% vs. 48% (RR = 1.79; 95% CI:
1.55–2.08) (moderate-quality evidence) [52]. When ivermectin was compared with thiabendazole,
there was no distinction in parasitological cure, i.e., 74% vs. 68% (RR = 1.07; 95% CI: 0.96–1.2),
but adverse events were less frequent with ivermectin (RR = 0.31; 95% CI: 0.20–0.50) than with
thiabendazole [52] (moderate certainty of evidence). No serious adverse events or deaths were
reported with either ivermectin or thiabendazole.
3.4. Resource use, Costs and Cost-Effectiveness
3.4.1. Strongyloidiasis
Three economic studies of moderate quality support a strategy of presumptive treatment for
strongyloidiasis in migrants from high-risk backgrounds [66–68]. One study showed potential cost
savings of universal treatment with albendazole compared with i) no intervention (watchful waiting);
and compared with ii) universal stool-based screening; in migrant populations in the U.S. [66].
Sensitivity analyses indicated a best-case scenario of large savings from presumptive treatment,
and a worst-case scenario in which treatment was still cost effective at the $30,000/QALY threshold
(1997 U.S. dollars).
The second study on presumptive treatment for strongyloidiasis in migrants living in the U.S.
in California and New York compared: i) presumptive treatment with albendazole for 3 or 5 days;
ii) presumptive treatment with one dose of ivermectin; iii) treatment in those with documented
eosinophilia; and iv) no intervention [67]. It indicated that presumptive treatment with ivermectin was
cost-effective at a threshold of less than USD 10,000 (EUR 9667) per QALY across a range of prevalence
values in migrants living in the U.S. [67]. This study did not include antibody detection among the
diagnostic tools. At a prevalence higher than 10%, treatment with ivermectin cost less than USD 2000
(EUR 1983) per QALY. These results were robust across a wide range of sensitivity analyses [67].
The third more recent study on presumptive treatment for hookworm and strongyloidiasis in
U.S.-bound Asian populations indicated that treatment in the destination country with albendazole and
ivermectin was likely to be cost-effective relative to no screening or screening and treatment strategies
in the country of origin among refugees from high-prevalence countries [68]. For strongyloidiasis,
overseas treatment cost less than USD 40,000 (EUR 31,092) per QALY gained at prevalence greater
than 1% and fell to less than USD 18,000 (EUR 13,991) per QALY gained at prevalence greater than 3%.
3.4.2. Schistosomiasis
There were no cost-effectiveness studies of screening and presumptive treatment in migrants
at risk of schistosomiasis. In non-migrant populations, a recent costing study compared the costs of
single and double KK tests with a urine dipstick test [69] for Sc. haematobium diagnosis in areas of high
endemicity. The results of this preliminary costing study indicated similar costs of around USD 6–7
(EUR 5–6) per test for single KK stool and urine tests; however, the quality of evidence for resource
use was low. A cost-effectiveness study by King et al. compared single-dose (40 mg/kg body weight)
and double-dose (40 mg/kg doses separated by 2–8 weeks) presumptive treatment with praziquantel
for schistosomiasis in high-prevalence (>40%) settings in Africa [65]. Double-dose praziquantel was
found deemed to be highly cost-effective (ICER of less than USD 500 (EUR 471)/QALY) compared
with single-dose treatment.
4. Discussion
The rationale for screening for strongyloidiasis and schistosomiasis in the EU/EEA and not other
parasitic infections is based on the estimated prevalence of these parasitic infections among migrants
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from endemic countries; potential prevention of fatal complications through early case detection
and treatment, and secondary transmission in asymptomatic patients based on a highly sensitive
test and very effective and safe treatment [11,35,36,71]. Therefore, the implementation of a screening
programme would allow early detection of the infection in individuals at risk, before they develop a
severe condition which may justify the screening itself.
Although quality data on the prevalence of schistosomiasis and strongyloidiasis among migrant
populations in the EU/EEA is limited, available data from endemic regions shows that prevalence of
schistosomiasis is between 20% and 40% and prevalence of strongyloidiasis is between 10% and
40% [3–5]. However, there is a rationale for public health surveillance for schistosomiasis and
strongyloidiasis to inform proper surveillance of mobile population from the regions [30]
Overall, systematic reviews showed that antibody-detecting serological tests are the most effective
screening tests for detection of schistosomiasis and strongyloidiasis in low-endemicity settings,
because they have higher sensitivity than conventional parasitological methods [19,44,45,50,53].
Newer serological tests were shown to be more effective than conventional techniques such as agar
plate culture and the Baermann method for strongyloidiasis and KK for Sc. mansoni. These conventional
techniques, as well as PCR, failed to detect infections of very low intensity [64] although they were
more specific than serological techniques [51,54]. They are also labor-intensive and require skilled
personnel and are therefore not recommended as the first option for screening [19]. In contrast,
serological testing is easier to perform in health facilities than collecting and testing faecal samples and
can also be combined with other infectious disease screening tests.
One limitation of antibody-detecting serological tests, particularly with schistosomiasis, is that
they cannot differentiate current from past infections; however, with strongyloidiasis, antibody titres
decline after treatment over time in most patients [62,72]. In addition, in immuno-compromised
patients, the sensitivity of serological tests may be reduced, and other additional screening methods
may be needed if serology is negative. In this regard, the utility of PCR assay as an alternative screening
method in immunosuppressed patients deserves further investigation.
Specifically, for Schistosoma spp. infections, available evidence shows that the IgM-ELISA [57],
IHA [46] and ICT IgG-IgM [61] tests were the most effective screening tests in low-endemicity countries.
In some low endemicity settings, two serological tests are performed, and a case is considered to be
positive if either test is positive; in others, a combination of ELISA testing and KK faecal examinations
is used to improve the accuracy of detection. However, Beltrame et al. advocate the use of the ICT
IgG-IgM test as a single screening test (negative predictive value >97%) [61].
For strongyloidiasis, available evidence (of very low to low quality) shows that antibody-detecting
blood tests using a variety of antigen preparations have a better detection rate than conventional
parasitological methods, with IVD-ELISA, Bordier-ELISA and NIE LIPS being the most accurate
tests [62]. Limitations of these serological tests include the large number of infective larvae required,
cross–reactions with other nematode infections and lower sensitivity in immuno-compromised
patients [19,62]. New tests based on the recombinant antigen Ss-NIE-1, although slightly less
sensitive, but currently considerably more expensive than other serological techniques, show excellent
specificity [62,63] and, although not widely available, they may be useful when designing rapid
tests [63].
For treatment of schistosomiasis, single-dose praziquantel is the drug of choice. Evidence from
systematic reviews shows that treatment with praziquantel significantly increased parasitological cure
and, achieved marked reductions in microhaematuria compared with placebo; praziquantel also has a
very good safety profile [47,48]. For treatment of strongyloidiasis, there is evidence (of low to moderate
quality) that ivermectin is more effective than albendazole [52] and evidence (of moderate quality) that
ivermectin is as effective as thiabendazole, but much better tolerated; no difference in the efficacy of
ivermectin was observed between endemic and non-endemic populations [52]. However, there are
no studies on the potential harms of large-scale administration of ivermectin (although widespread
experience with filariasis control is reassuring).
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Implementing presumptive treatment either with ivermectin or praziquantel requires additional
complex screening strategies to identify individuals with loiasis or neurocysticercosis for whom these
drugs might be inappropriate [70,71] and recently published recommendations specify that immigrants
arriving from endemic areas should undergo a thorough clinical screening before being given either
praziquantel or albendazole [73]. In addition, ivermectin is not readily available in most endemic and
non-endemic countries and has limited approval by regulatory authorities in the EU/EEA.
We found no studies evaluating the cost-effectiveness of schistosomiasis screening and treatment
interventions in migrant populations. For schistosomiasis, no studies were available on the cost
of screening tests based on antibody detection in the non-endemic setting. In endemic settings,
double-dose praziquantel was deemed to be highly cost-effective compared with a single dose and
was considered robust to plausible changes in parameter estimates [65]. Further economic studies are
required to provide better data on the cost-effectiveness of a test-and-treat strategy for schistosomiasis
in non-endemic countries. For strongyloidiasis, three studies indicated that presumptive treatment
with albendazole or ivermectin was cost-saving or cost-effective, in migrants to the U.S. or in endemic
settings [66–68]. The limitations of these studies may decrease the relevance of the results for migrant
populations in the EU/EEA. Most of the economic studies identified were limited to Asian populations
and not based on screening with antibody testing in a non-endemic setting. However, where the
prevalence of schistosomiasis and strongyloidiasis is greater than 1% and the price of presumptive
treatment is similar to that used in the economic evaluations identified in this review, presumptive
treatment with ivermectin or albendazole is likely to be cost-effective for migrants to the EU/EEA.
The strengths of our study include the use of the GRADE methodology to evaluate the quality and
strength of the evidence and effect size in the included studies. The primary outcomes—parasitological
cure or failure for efficacy of treatment and accuracy for screening—were objective measures.
The individual studies in the included systematic reviews originated from different regions and
countries with moderate to high endemicity for both parasites, increasing the generalizability of
the results.
We did not identify any systematic reviews or RCTs on screening for schistosomiasis and
strongyloidiasis in newly arrived migrants to EU/EEA. RCTs on preventive screening are rare,
and so we used a logic model approach, as recommended at US Task Force on Preventive Health
Care, and present data on population prevalence, diagnostic accuracy, treatment effectiveness and
cost-effectiveness [70,74]. Other limitations include the lack of accurate data on the prevalence of
schistosomiasis and strongyloidiasis among migrants from endemic countries entering the EU/EEA
and the lack of data on the cost-effectiveness of screening and treating migrants for these parasitic
infections. Further studies evaluating the effectiveness and cost-effectiveness of screening intervention
in migrant populations are warranted.
The results of this systematic review indicate that although the certainty of desirable over
undesirable effects of screening mobile and high-risk migrant populations from endemic areas is
low to moderate, there is a rationale for screening, particularly in immunosuppressed patients
since there is a high value placed on uncertain but potentially life-preserving benefits as suggested
elsewhere [75]. Both schistosomiasis and strongyloidiasis can become chronic and cause severe
long-term complications if untreated and the health benefits of intervention therefore outweigh
its potential harms. Effective diagnostic tests are available and treatments for both infections are
efficacious, well tolerated and safe with few exceptions [48,52,54,62].
Presumptive single-dose therapy of strongyloidiasis with ivermectin for all migrants is likely to
be cost-effective; however, the feasibility of this measure has not been demonstrated in clinical studies
in non-endemic settings. Importantly, implementing presumptive treatment either with ivermectin for
strongyloidiasis or praziquantel for schistosomiasis requires additional screening strategies to identify
individuals for whom these drugs might be harmful.
The evidence suggest screening should target people arriving from endemic areas, but national
screening strategies will need to be tailored to the specific context of individual EU/EEA countries
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and, in particular, the countries of origin of migrants to those countries. Although, there are no
studies on the extent to which multiple screening tests for infectious diseases in migrants can improve
cost-effectiveness, integrating innovative public health screening strategies for schistosomiasis and
strongyloidiasis with other infectious diseases will improve surveillance data as well as reduce costs.
However, the optimal approach to delivery of screening will need to consider a global perspective,
as well as depend on the health system context in individual EU/EEA countries. In this regard,
addressing lack of access to healthcare for migrants, heterogeneity of screening strategies applicable
in member states, and improving health professionals’ knowledge and training of migrant related
infectious diseases should improve the responsiveness of the public health care system with regards to
coverage and uptake of screening at the level of primary health care.
Finally, although we consider that sufficient evidence exists to justify screening for strongyloidiasis
and schistosomiasis immigrants coming to the EU/EEA from endemic areas, further assessment of
the benefits and risks of screening and treatment is needed. More specifically, additional economic
analysis is required, in particular to evaluate the costs of a test and treat strategy and to compare the
cost-effectiveness of screening and of presumptive treatment.
5. Conclusions
This systematic review provides a compendium of indirect evidence that support the screening
for strongyloidiasis and schistosomiasis in migrants coming from endemic areas to the EU/EEA,
and particularly in immunosuppressed or at-risk-of immunosuppression patients.
Screening for strongyloidiasis and schistosomiasis should be considered based on serological
testing in the absence of immunosuppression. Ivermectin and praziquantel have demonstrated
a high efficacy, an excellent safety profile, and a potentially easy schedule for the treatment of
strongyloidiasis and schistosomiasis. Economic modelling suggests presumptive single-dose treatment
of strongyloidiasis with ivermectin for all migrants is likely cost-effective, but the feasibility of this
strategy has yet to be demonstrated in clinical studies in non-endemic settings.
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1. Literature search strategy for systematic review
The used search strategies for the identification of systematic reviews are listed here.
A. Database: Ovid MEDLINE(R) 1946 to Present with Daily Update
Search Date: 15 April 2016
——————————————————————————–
1. exp Schistosoma/ (15595)
2. bilharzia$.tw. (2431)
3. exp Schistosomiasis/ (21432)
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4. schistosom$.tw. (25367)
5. katayama fever$.tw. (30)
6. or/1–5 (30014)
7. Strongyloides/ (985)
8. Strongyloides stercoralis/ (1044)
9. Strongyloidiasis/ (3301)
10. strongyloid$.tw. (3988)
11. or/7–10 (4959)
12. 6 or 11 (34621)
13. exp Mass Screening/ (107821)
14. (screened or screening?) tw. (417896)
15. Early Diagnosis/ (19041)
16. (detected or detection? or diagnos$ or discover$ or indentif$) tw. (2972048)
17. exp Population Surveillance/ (56090)
18. (disease? adj2 surveillance) tw. (4053)
19. Contact Tracing/ (3521)
20. contact tracing tw. (1152)
21. or/13–20 (3301561)
22. meta analysis mp, pt. (91365)
23. review pt. (2035657)
24. search$ tw. (253765)
25. or/22–24 (2222329)
26. animals/ not (humans/ and animals/) (4194238)
27. 25 not 26 (2065589)
28. 12 and 21 and 27 (711)
29. 28 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$) ed. (222)
30. remove duplicates from 29 (218)
***************************
B. Database: Embase <1980 to 2016 April 14>
Search Date: 15 April 2016
——————————————————————————–
1. exp Schistosoma/ (19846)
2. bilharzia$.tw. (2115)
3. exp schistosomiasis/ (20241)
4. schistosom$.tw. (26744)
5. katayama fever$.tw. (40)
6. or/1–5 (33204)
7. Strongyloides/ (1220)
8. Strongyloides stercoralis/ (2315)
9. strongyloidiasis/ (3835)
10. strongyloid$.tw. (4704)
11. or/7–10 (6600)
12. 6 or 11 (39071)
13. exp mass screening/ (178654)
14. (screened or screening?).tw. (614882)
15. early diagnosis/ (82347)
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16. parasite identification/ (13161)
17. ((case? or early or parasit$) adj5 (detected or detection? or diagnos$ or discover$ or egg or
indentif$)).tw. (385884)
18. exp health survey/ (182738)
19. (disease? adj2 surveillance).tw. (5156)
20. contact examination/ (2830)
21. contact tracing.tw. (1448)
22. or/13–21 (1237076)
23. meta analys$.mp. (167508)
24. search$.tw. (362044)
25. review.pt. (2131214)
26. or/23–25 (2472677)
27. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or
humans) ti.) (5499319)
28. 26 not 27 (2251777)
29. 12 and 22 and 28 (455)
30. 29 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$) dd. (195)
31. remove duplicates from 30 (190)
***************************
C. Database: EBSCO CINAHL <1970 to April 2016>
Search Date: 15 April 2016
——————————————————————————–
# Query Limiters/Expanders Last Run Via Results
S28 S24 AND S27 129
S27 S25 OR S26 2,596,403
S26 EM 2010 or EM 2011 or EM 2012 or EM 2013 or EM 2014 or EM 2015 or EM 2016 2,415,478
S25 PY 2010 or PY 2011 or PY 2012 or PY 2013 or PY 2014 or PY 2015 or PY 2016 2,346,296
S24 S9 AND S17 AND S23 253
S23 S18 OR S19 OR S20 OR S21 OR S22 221,252
S22 (TI meta analy * or AB meta analy *) 29,697
S21 (MH “Meta-Analysis”) 24,939
S20 PT review 141,448
S19 PT systematic review 53,358
S18 (MH “Systematic Review”) 37,435
S17 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 1,246,183
S16 TX contact tracing 2230
S15 TX (disease * or population) N2 surveillance 23,893
S14 (MH “Population Surveillance+”) 5949
S13 TX (detected or detection * or diagnos * or discover * or indentif *) 1,184,038
S12 (MH “Early Diagnosis”) 4472
S11 TI ((screened or screening *) OR AB (screened or screening *)) 78,236
S10 (MH “Health Screening+”) 62,744
S9 S5 OR S8 5460
S8 S6 OR S7 4460
S7 TX strongyloid * 529
S6 (MH “Helminthiasis+”) 4132
S5 S1 OR S2 OR S3 OR S4 1931
S4 TX katayama fever 25
S3 TX bilharzia * 175
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S2 TX schistosome * 1871
S1 (MH “Schistosomiasis+”) 756
***************************
D. Databases: Database of Abstracts of Reviews of Effects (DARE) and Cochrane Database of
Systematic Reviews (CDSR)
Search Date: 15 April 2016
——————————————————————————–
ID Search
#1 MeSH descriptor: [Schistosoma] explode all trees
#2 bilharzia *
#3 MeSH descriptor: [Schistosomiasis] explode all trees
#4 schistosom *
#5 katayama fever
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Strongyloides] this term only
#8 MeSH descriptor: [Strongyloides stercoralis] this term only
#9 MeSH descriptor: [Strongyloidiasis] this term only
#10 strongyloid *
#11 #7 or #8 or #9 or #10
#12 #6 or #11
#13 #12 in Other Reviews
#14 #12 in Cochrane Reviews (Reviews and Protocols)
***************************
2. Literature search strategy for systematic search for cost-effectiveness studies
The used search strategies for the identification of systematic reviews on cost-effectiveness are
listed here.
A. Database: Ovid MEDLINE(R) Epub Ahead of Print <May Week 3 2016>, Ovid MEDLINE(R)
1946 to Present with Daily Update
Search Date: 31 May 2016
——————————————————————————–
1. exp Schistosoma/ (15714)
2. bilharzia$.tw. (2438)
3. exp Schistosomiasis/ (21583)
4. schistosom$.tw. (25722)
5. katayama fever$.tw. (30)
6. or/1–5 (30381)
7. Strongyloides/ (990)
8. Strongyloides stercoralis/ (1056)
9. Strongyloidiasis/ (3319)
10. strongyloid$.tw. (4079)
11. or/7–10 (5051)
12. 6 or 11 (35067)
13. exp Mass Screening/ (108535)
14. (screened or screening? or tested or testing or tests).tw. (1734474)
15. Early Diagnosis/ (19350)
16. (detected or detection? or diagnos$ or discover$ or indentif$).tw. (3053822)
17. exp Population Surveillance/ (56687)
18. (disease? adj2 surveillance).tw. (4195)
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19. Contact Tracing/ (3563)
20. contact tracing.tw. (1176)
21. or/13–20 (4387118)
22. meta analysis.mp,pt. (96759)
23. review.pt. (2060867)
24. search$.tw. (266775)
25. guideline.pt. (15780)
26. guideline/ (15780)
27. guidelines as topic/ (34071)
28. practice guideline.pt. (21216)
29. practice guideline/ (21216)
30. practice guidelines as topic/ (91792)
31. (CPG or CPGs or guidance or guideline? or recommend$ or standard?).ti. (147179)
32. exp clinical pathway/ (5273)
33. exp clinical protocol/ (139345)
34. ((care or clinical) adj2 pathway?).tw. (5129)
35. or/22–34 (2572065)
36. 12 and 21 and 35 (960)
37. animals/ not (humans/ and animals/) (4215704)
38. 36 not 37 (838)
39. 38 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).ed. (271)
40. remove duplicates from 39 [reviews and guidelines] (261)
41. exp "costs and cost analysis"/ (197942)
42. cost$.mp. (467877)
43. cost effective$.tw. (83090)
44. cost benefit analys$.mp. (67319)
45. health care costs.mp. (37157)
46. or/41–45 (477217)
47. 12 and 21 and 46 (260)
48. animals/ not (humans/ and animals/) (4215704)
49. 47 not 48 (222)
50. 49 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).ed. (82)
51. remove duplicates from 50 (78)
***************************
B. Database: Embase <1974 to 2016 Week 22>
Search Date: 31 May 2016
——————————————————————————–
1. exp Schistosoma/ (21727)
2. bilharzia$.tw. (2492)
3. exp schistosomiasis/ (21930)
4. schistosom$.tw. (29047)
5. katayama fever$.tw. (42)
6. or/1–5 (36157)
7. Strongyloides/ (1229)
8. Strongyloides stercoralis/ (2447)
9. strongyloidiasis/ (3986)
10. strongyloid$.tw. (4977)
Int. J. Environ. Res. Public Health 2019, 16, 11 32 of 41
11. or/7–10 (6962)
12. 6 or 11 (42352)
13. exp mass screening/ (182895)
14. (screened or screening? or tested or testing or tests).tw. (2429856)
15. early diagnosis/ (83110)
16. parasite identification/ (13222)
17. ((case? or early or parasit$) adj5 (detected or detection? or diagnos$ or discover$ or egg or
indentif$)).tw. (405389)
18. exp health survey/ (184236)
19. (disease? adj2 surveillance).tw. (5253)
20. contact examination/ (2867)
21. contact tracing.tw. (1512)
22. or/13-21 (2999272)
23. meta analys$.mp. (170914)
24. search$.tw. (371898)
25. review.pt. (2163187)
26. guideline.pt. (0)
27. guideline/ (144)
28. guidelines as topic/ (229895)
29. practice guideline.pt. (0)
30. practice guideline/ (275502)
31. practice guidelines as topic/ (171091)
32. (CPG or CPGs or guidance or guideline? or recommend$ or standard?).ti. (203285)
33. exp clinical pathway/ (6983)
34. exp clinical protocol/ (75932)
35. ((care or clinical) adj2 pathway?).tw. (9455)
36. or/23–35 (2900847)
37. 12 and 22 and 36 (824)
38. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or
humans).ti.) (5865460)
39. 37 not 38 (678)
40. 39 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).dd. (304)
41. remove duplicates from 40 [reviews and guidelines] (295)
42. cost effectiveness analysis/ (114264)
43. cost.tw. (387431)
44. costs.tw. (208732)
45. or/42–44 (544771)
46. 12 and 22 and 45 (274)
47. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or
humans).ti.) (5865460)
48. 46 not 47 (223)
49. 48 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).dd. (115)
50. remove duplicates from 49 [costing] (111)
***************************
C. Databases: Database of Abstracts of Reviews of Effects (DARE) and Cochrane Database of
Systematic Reviews (CDSR) and NHS EED
Search Date: 31 May 2016
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ID Search
#1 MeSH descriptor: [Schistosoma] explode all trees
#2 bilharzia*
#3 MeSH descriptor: [Schistosomiasis] explode all trees
#4 schistosom*
#5 katayama fever
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Strongyloides] this term only
#8 MeSH descriptor: [Strongyloides stercoralis] this term only
#9 MeSH descriptor: [Strongyloidiasis] this term only
#10 strongyloid*
#11 #7 or #8 or #9 or #10
#12 #6 or #11
#13 #12 in Other Reviews
#14 #12 in Cochrane Reviews (Reviews and Protocols)
#15 #12 in Economic Evaluations
***************************
D. Database: EBSCO CINAHL <1970 to May 2016>
Search Date: 31 May 2016
——————————————————————————–
# Query Limiters/Expanders Last Run Via Results
S38 S32 AND S37 38
S37 S9 AND S17 AND S36 76
S36 S34 OR S35 139,767
S35 TI (cost OR costs) OR AB (cost OR costs) 89,616
S34 (MH “Costs and Cost Analysis+”) 82,915
S33 S29 AND S32 164
S32 S30 OR S31 2,653,954
S31 EM 2010 or EM 2011 or EM 2012 or EM 2013 or EM 2014 or EM 2015 or EM 2016 2,445,432
S30 PY 2010 or PY 2011 or PY 2012 or PY 2013 or PY 2014 or PY 2015 or PY 2016 2,403,611
S29 S9 AND S17 AND S28 307
S28 S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 348,353
S27 TX (care or clinical) N2 pathway * 15,555
S26 TI (CPG or CPGs or guidance or guideline * or recommend * or standard *) 79,261
S25 (MH “Critical Path”) 4120
S24 PT Practice Guidelines 9487
S23 (MH “Practice Guidelines”) 53,690
S22 (TI meta analy * or AB meta analy *) 30,542
S21 (MH “Meta Analysis”) 25,200
S20 PT review 144,019
S19 PT systematic review 53,350
S18 (MH “Systematic Review”) 37,846
S17 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 1,801,344
S16 TX contact tracing 2236
S15 TX (disease * or population) N2 surveillance 24,089
S14 (MH “Population Surveillance+”) 6026
S13 TX (detected or detection * or diagnos * or discover * or indentif *) 1,195,388
S12 (MH “Early Diagnosis”) 4553
S11 TX (screened or screening * or tested or testing or tests) 1,102,848
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S10 (MH “Health Screening+”) 63,147
S9 S5 OR S8 5501
S8 S6 OR S7 4500
S7 TX strongyloid * 537
S6 (MH “Helminthiasis+”) 4167
S5 S1 OR S2 OR S3 OR S4 1942
S4 TX katayama fever 24
S3 TX bilharzia * 175
S2 TX schistosome * 1881
S1 (MH “Schistosomiasis+”) 764
***************************
E. Databases: PubMed
Search Date: 31 May 2016
——————————————————————————–
((((((((schistosome * or bilharzia * or katayama or strongyloid *))) AND ((screened or screening
* or tested or testing or tests)))) AND (((CPG or CPGs or guidance or guideline * or metaanalysis or
meta-analysis or recommend * or review or standard or standards)))) AND ((publisher [3]))))) (8)
((((((((schistosome * or bilharzia * or katayama or strongyloid *))) AND ((screened or screening *
or tested or testing or tests)))) AND (((cost or costs)))) AND ((publisher [3]))))) (2)
***************************
3. Update Literature strategy for primary studies on diagnostic or screening tools for
schistosomiasis.
A. Database: Ovid MEDLINE(R)—1946 to February 2017.
1. Schistosomiasis/ (13485)
2. Schistosomiasis.mp. (24533)
3. snail fever.mp. (10)
4. schistosome *.mp. (5528)
5. exp "Sensitivity and Specificity"/ (495027)
6. sensitivity.tw. (638974)
7. specificity.tw. (379605)
8. ((pre-test or pretest) adj probability).tw. (1695)
9. post-test probability.tw. (441)
10. predictive value$.tw. (85102)
11. likelihood ratio$.tw. (11639)
12. or/5–11 (1217873)
13. or/1–4 (26340)
14. 12 and 13 (1493)
15. limit 14 to humans (1112)
16. from 15 keep 1001–1112 (112)
A. Database: EMBASE—up to February 2017
#16 #14 AND ‘human’/de AND [embase]/lim NOT [medline]/lim 308
#15 #14 AND ‘human’/de 1489
#14 #5 AND #13 2534
#13 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 1688887
#12 ‘sensitivity and sensibility’ 982
#11 ‘sensitivity’ 1132406
#10 ‘specificity’ 719846
#9 ‘pretest posttest design’ 2331
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#8 ‘predictive value’ 161458
#7 ‘likelihood ratio’ 11832
#6 ‘diagnostic accuracy’ 220669
#5 #1 OR #2 OR #3 OR #4 35984
#4 ‘snail fever’ 9
#3 ‘schistosome’ 4643
#2 ‘schistosoma’ 25091
#1 ‘schistosomiasis’/exp 22890
B. Database: COCHRANE LIBRARY- up to February 2017
ID Search Hits
#1 MeSH descriptor: [Schistosomiasis] explode all trees 295
#2 Schistosomiasis 497
#3 snail fever 3
#4 schistosome * 50
#5 #1 or #2 or #3 or #4 506
#6 MeSH descriptor: [Diagnosis] explode all trees 298999
#7 diagno * 129750
#8 #6 or #7 367644
#9 #5 and #8 220
C. Database: CINAHL—up to February 2017
S12 S4 AND S11
S11 S5 OR S6 OR S7 OR S8 OR S9 OR S10
S10 likelihood ratio$
S9 predictive value$
S8 post-test probability
S7 sensitivity and specificity
S6 specificity
S5 sensitivity
S4 S1 OR S2 OR S3
S3 schistosoma
S2 schistosome *
S1 Schistosomiasis
D. Database: LILACS – up to February 2017
(tw:((tw:(esquistosomiasis)) OR (tw:(bilharziasis)) OR (tw:(schistosoma)))) AND
(tw:((tw:(diagnostico)) OR (tw:(deteccion)))) AND (instance:”regional”) AND (db:(“LILACS”
OR “colecionaSUS” OR “IBECS” OR “SES-SP” OR “MedCarib” OR “CUMED”) AND
clinical_aspect:(“diagnosis”) AND limit:(“humans”))
***************************
4. Update Literature strategy for primary studies on diagnostic or screening tools for
strongyloidiasis
A. Database: Ovid MEDLINE(R)—1946 to February 2017
1. Strongyloidiasis/ (3403)
2. Strongyloidiasis.mp. (3747)
3. Strongyloides stercoralis/ (1098)
4. Strongyloides stercoralis.mp. (2142)
5. or/1–4 (4376)
6. exp “Sensitivity and Specificity”/ (494358)
7. sensitivity.tw. (637846)
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8. specificity.tw. (379066)
9. ((pre-test or pretest) adj probability).tw. (1689)
10. post-test probability.tw. (438)
11. predictive value$.tw. (84929)
12. likelihood ratio$.tw. (11613)
13. or/6–12 (1216076)
14. 5 and 13 (247)
15. limit 14 to humans (207)
B. Database: EMBASE—up to February 2017
No. Query Results
#14 #12 AND [embase]/lim NOT [medline]/lim AND ‘human’/de 136
#13 #12 AND [embase]/lim NOT [medline]/lim 156
#12 #3 AND #11 472
#11 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 1686971
#10 ‘diagnostic accuracy’ 220414
#9 ‘likelihood ratio’ 11815
#8 ‘predictive value’ 161090
#7 ‘pretest posttest design’ 2315
#6 ‘specificity’ 719056
#5 ‘sensitivity’ 1131076
#4 ‘sensitivity and sensibility’ 981
#3 #1 OR #2 5662
#2 ‘strongyloides stercoralis’ 3193
#1 ‘strongyloidiasis’/exp 4162
C. Database: COCHRANE LIBRARY—up to February 2017
ID Search Hits
#1 MeSH descriptor: [Strongyloidiasis] explode all trees 28
#2 Strongyloidiasis 53
#3 MeSH descriptor: [Strongyloides stercoralis] explode all trees 12
#4 Strongyloides stercoralis 47
#5 #1 or #2 or #3 or #4 72
#6 MeSH descriptor: [Diagnosis] explode all trees 298999
#7 diagno * 129739
#8 #6 or #7 367633
#9 #5 and #8 38
D. Database: CINAHL—up to February 2017
Términos de la búsqueda Opciones de búsqueda
S11 (S4 OR S5 OR S6 OR S7 OR S8 OR S9) AND (S3 AND S10)
S10 S4 OR S5 OR S6 OR S7 OR S8 OR S9
S9 likelihood ratio$
S8 predictive value$
S7 post-test probability
S6 sensitivity and specificity
S5 specificity
S4 sensitivity
S3 S1 OR S2
S2 strongyloides stercoralis
S1 strongyloidiasis
Int. J. Environ. Res. Public Health 2019, 16, 11 37 of 41
E. Database: LILACS—up to February 2017
(tw:((tw:(estrongiloidiasis)) OR (tw:(Strongyloides stercoralis)))) AND (tw:((tw:(diagnostico)) OR
(tw:(deteccion))))
***************************
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